Test ID BUAUC Busulfan, Intravenous Dose, Area Under the Curve, Plasma
Necessary Information
The time the drug administration is started and completed, the patient's dose (mg every 6 hours), body weight (kg), and age (years) must be submitted with the specimens. Without infusion start time, exact time of specimen collection, dose, and body weight, the area under the curve and clearance cannot be calculated. Age is required for assessment of the correct dose per body weight.
A completed Busulfan Information: Mail-In Specimen Instructions (T559) is required.
Specimen Required
Four plasma specimens with different collection times (keep all specimens under 1 order) are required.
Collection Container/Tube: Green top (sodium heparin) (Plasma gel/PST are not acceptable)
Submission Container/Tube: Plastic vials
Specimen Volume: 1 mL
Collection Instructions:
1. The first specimen should be collected immediately after completion of the first intravenous infusion of 0.8 mg/kg busulfan.
2. Additional specimens should also be collected at 1 hour, 2 hours, and 4 hours after completion of infusion.
3. Label each specimen with exact time of collection.
4. Busulfan degrades quickly at ambient temperature. Specimens must be kept in wet ice slurry or refrigerated at 4° C. Specimens must be centrifuged within 2 hours after collection. Separate the plasma and transfer to individual 5-mL plastic vials, labeled with exact time of collection. Immediately freeze at -20° C.
Additional Information:
This test should only be ordered when the following criteria are met:
-Busulfan dosing protocol must be intravenous administration of 0.8 mg/kg doses every 6 hours over 4 days, for a total of 16 doses
-Specimens must be collected as described below:
-1 specimen collected immediately after completion of the first 2-hour IV infusion of busulfan
-1 specimen collected 1 hour after the infusion is completed
-1 specimen collected 2 hours after the infusion is completed
-1 specimen collected 4 hours after the infusion is completed and prior to the next infusion of busulfan
Forms
1. Busulfan Information: Mail-In Specimen Instructions (T559) is required
2. If not ordering electronically, complete, print, and send a Therapeutics Test Request (T831) with the specimen.
Useful For
Guiding dosage adjustments to achieve complete bone marrow ablation while minimizing dose-dependent toxicity
Profile Information
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
DOSE | Busulfan, IV Dose, AUC, P | No | Yes |
BU2H | Busulfan, Immediate Post Infusion | No | Yes |
BU3H | Busulfan, 1hr Post Infusion | No | Yes |
BU4H | Busulfan, 2hr Post Infusion | No | Yes |
BU6H | Busulfan, 4hr Post Infusion | No | Yes |
Special Instructions
Method Name
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
Reporting Name
Busulfan, IV Dose, AUC, PSpecimen Type
Plasma Na HeparinSpecimen Minimum Volume
0.25 mL
Specimen Stability Information
Specimen Type | Temperature | Time | |
---|---|---|---|
Plasma Na Heparin | Frozen (preferred) | 28 days | |
Refrigerated | 72 hours |
Clinical Information
Busulfan is an alkylating agent used to ablate bone marrow cells prior to hematopoietic stem cell transplantation for chronic myelogenous leukemia.(1) Busulfan is typically administered intravenously (IV) at the recommended dosage of 0.8 mg/kg of actual or ideal body weight (whichever is lower) and given once every 6 hours over 4 days for a total of 16 doses. Dose-limiting toxicity of busulfan includes veno-occlusive liver disease, seizures, and coma. To avoid toxicity while ensuring busulfan dose adequacy to completely ablate the bone marrow, IV dosing should be guided by a pharmacokinetic (PK) evaluation of the area under the curve and clearance after the first dose.(2) The PK evaluation should be carried out at the end of the first dose, with results of PK testing available to facilitate dose adjustment before beginning the fifth dose.
Reference Values
AREA UNDER THE CURVE
900-1500 (mcmol/L)(min)
CLEARANCE
2.1-3.5 (mL/minute)/kg
Cautions
Failure to provide the 4 plasma specimens as described will invalidate the area under the curve calculations.
Day(s) Performed
Monday through Saturday
Report Available
Same day/1 to 3 daysPerforming Laboratory

Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
80299 x 4